用chatgpt写论文能过查重吗 AI | ChatGPT写文章查重不过关

笔者使用[1]写了一篇短文，然后使用专业的查重软件[2]来进行检测。结果发现其重复率为30%，然而最新研发的AI检测工具发现该短文100%是由AI生成的。随后笔者再次使用GPT对其进行润色和降重，虽然重复率降下去了，但是还是没有逃过AI检测工具的火眼金睛。不得不说，这为大家在无脑使用写（水）论文时敲响了警钟。不要什么东西都依赖于GPT，理应理性合理地使用。

1 生成短文

用地道的英语写一篇2000字左右的“PD1/PDL1小分子抑制剂研究现状”的综述性学术文章

2 GPT给出短文内容

Introduction
PD1/PDL1 small molecule inhibitors have emerged as a promising class of drugs for the treatment of various cancers. These inhibitors target the programmed cell death protein 1 (PD1) and its ligand, programmed death-ligand 1 (PDL1), which are key components of the immune checkpoint pathway. By blocking the PD1/PDL1 interaction, these inhibitors can enhance the immune response against cancer cells and improve patient outcomes. In this article, we will review the current state of research on PD1/PDL1 small molecule inhibitors, including their mechanism of action, clinical applications, and potential future directions.

Mechanism of action
PD1 is a receptor expressed on the surface of T cells, which plays a crucial role in regulating the immune response. When PD1 binds to its ligand, PDL1, it inhibits T cell activation and proliferation, thereby allowing cancer cells to evade immune surveillance. PD1/PDL1 small molecule inhibitors work by blocking this interaction, thereby releasing the brakes on the immune system and allowing T cells to attack cancer cells.
Several small molecule inhibitors have been developed to target PD1/PDL1, including nivolumab, pembrolizumab, atezolizumab, and durvalumab. These drugs have shown promising results in preclinical and clinical studies, with high response rates and durable responses in patients with various types of cancer.

Clinical applications
PD1/PDL1 small molecule inhibitors have shown efficacy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and bladder cancer. In clinical trials, these drugs have demonstrated high response rates and durable responses in patients who have failed conventional therapies.
One of the most promising applications of PD1/PDL1 small molecule inhibitors is in combination with other therapies, such as chemotherapy, radiation therapy, and targeted therapy. Combining these inhibitors with other treatments can enhance their efficacy and improve patient outcomes. For example, pembrolizumab combined with chemotherapy has been shown to improve overall survival and progression-free survival in patients with NSCLC.

Future directions
Despite the success of PD1/PDL1 small molecule inhibitors in the clinic, there are several challenges that remain to be addressed. One major challenge is identifying biomarkers that can predict response to these drugs. Currently, there are no reliable biomarkers that can predict which patients will respond to PD1/PDL1 inhibitors, and this limits their clinical utility.
Another challenge is overcoming resistance to these drugs. Although PD1/PDL1 inhibitors can induce durable responses in many patients, some patients develop resistance over time, which limits their long-term efficacy. Identifying the mechanisms of resistance and developing strategies to overcome them will be an important area of research in the future.

Conclusion
PD1/PDL1 small molecule inhibitors have revolutionized the treatment of cancer, offering a new approach to harnessing the power of the immune system to fight cancer cells. These drugs have shown significant promise in clinical trials, with high response rates and durable responses in patients with various types of cancer. However, challenges remain in identifying biomarkers that can predict response and overcoming resistance to these drugs. Future research in these areas will be critical to further optimize the use of PD1/PDL1 small molecule inhibitors in cancer therapy.

3 生成短文标题

为上文加一个标题

4 获得短文标题

"PD1/PDL1 Small Molecule Inhibitors: Current Research Status and Future Directions"

5 查重

查重结果

AI生成比例

虽然重复率为30%，但令人震惊的是，判定该文百分之百由AI生成。不过确实也符合真实情况。所以想完完全全依靠GPT写（水）论文在未来是不太现实的。笔者合理怀疑，未来很有可能会将学术论文中AI生成率列入论文查重范围。

6 润色与降重

对上述短文使用GPT润色并降重。虽然重复率从30%降低到19%，但是仍然检测到这篇论文百分之百出自AI之手。

润色降重结果参考资料

[1]

:

[2]

:

323AI导航网发布